Definium Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Definium Therapeutics, Inc. (DFTX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $21.46 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Definium Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was 1.53 CAD/shares.
- Definium Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was 18.96 CAD/shares, a 591.97% increase from fiscal 2021.
- Definium Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was 2.74 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2022-12-31 | 18.96 CAD/shares 10-K · filed 2023-03-09 | |||
| 2022-09-30 | 19.45 CAD/shares 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | 1.43 CAD/shares 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 1.53 CAD/shares 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | 2.74 CAD/shares 10-K · filed 2022-03-28 |
USD/shares
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.46 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $17.12 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $8.12 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $7.66 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $6.95 10-Q · filed 2025-07-31 | |||
| 2025-03-31 | $6.65 10-Q · filed 2025-05-08 | |||
| 2024-09-30 | $5.51 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $5.08 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | $3.38 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $3.38 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $3.38 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $2.98 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |